002923 Zhuhai Rundu Pharmaceutical
- 10.63
- +0.16+1.53%
Zhuhai Rundu Pharmaceutical News
Rundu Co., Ltd. (002923.SZ) plans to pay 2 yuan for 10 shares to be deducted from interest on May 31
Rundu Co., Ltd. (002923.SZ) announced that the company's 2023 equity distribution plan: to all shareholders every 10...
There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings
The market was pleased with the recent earnings report from Zhuhai Rundu Pharmaceutical Co., Ltd. (SZSE:002923), despite the profit numbers being soft. We think that investors might be looking at som
Rundu Co., Ltd. (002923.SZ): Net profit of 29.055,800 yuan in the first quarter decreased by 28.14% year-on-year
On April 26, Ge Longhui Co., Ltd. (002923.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 306 million yuan, down 14.82% year on year; net profit attributable to shareholders of listed companies was 29.0558 million yuan, down 28.14% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 255.725 million yuan, down 29.80% year on year; basic earnings per share were 0.09 yuan.
Rundu Co., Ltd. (002923.SZ): The product application range covers various fields such as peptic ulcer, hypertension, surgical anesthesia, antipyretic analgesia, anti-infective, and diabetes
Gelonghui, April 9 | Rundu Co., Ltd. (002923.SZ) said on the investor interactive platform that the company is a modern technology-based pharmaceutical enterprise integrating drug R&D, production and sales. Its main business is R&D, production and sales of chemical preparations, chemical raw materials, pharmaceutical intermediates. The product application range covers peptic ulcers, hypertension, surgical anesthesia, antipyretic analgesia, anti-infective, diabetes, etc. Nicotine is a new business field that the company has expanded in recent years, and has now formed a certain level of commercial sales. The company will actively adjust the strategic plan according to the market environment to seek more opportunities for commercial cooperation
Rundu Co., Ltd. (002923.SZ): Reganosheng obtained a notice of approval for the marketing application of chemical raw materials
Gelonghui, March 29 | Rundu Co., Ltd. (002923.SZ) announced that the company recently received the approval and issuance of Reganosin (hereinafter referred to as “this product”) “Notice of Approval of the Marketing Application for Chemical Ingredients” from the China Drug Administration. This product is an important part of the company's industrial chain in the field of cardiac stress medication. With the application and promotion of cardiac stress drugs in the field of coronary heart disease diagnosis, it is expected to benefit more patients.
Optimistic Investors Push Zhuhai Rundu Pharmaceutical Co., Ltd. (SZSE:002923) Shares Up 25% But Growth Is Lacking
Those holding Zhuhai Rundu Pharmaceutical Co., Ltd. (SZSE:002923) shares would be relieved that the share price has rebounded 25% in the last thirty days, but it needs to keep going to repair the rece
Rundu Co., Ltd. (002923.SZ): Not involved in artificial intelligence-assisted new drug development
Gelonghui, March 21丨Some investors asked Rundu Co., Ltd. (002923.SZ) on the investor interactive platform, “Does the company use artificial intelligence to assist in the development of new drugs?” The company replied that the company has not yet involved artificial intelligence-assisted research and development of new drugs.
Rundu Co., Ltd. (002923.SZ): The existing production capacity of the alkaloid (nicotine) project can meet sales needs
Gelonghui March 8 | Rundu Co., Ltd. (002923.SZ) held an investor relationship on March 6, 2024. Regarding “What is the progress of the alkaloid (nicotine) business now? How much production capacity does the company have in this area? What position is it in the industry?” The company replied that the alkaloid (nicotine) business is developing normally. The current production capacity of the company's alkaloid (nicotine) project can meet sales needs. Alkaloids can be used in various fields such as medicine, pesticides, e-cigarettes, oral cigarettes, nicotine patches, etc., and have a wide range of applications. At present, the company has formed a certain level of commercial sales and is in accordance with local market entry mechanisms
Rundu Co., Ltd. (002923.SZ): Overseas revenue is mainly generated from the sales business of APIs and intermediates
Gelonghui March 8 | Rundu Co., Ltd. (002923.SZ) held an investor relationship on March 6, 2024. Regarding “What part of the business is the company's overseas revenue mainly?” The company replied that the company's overseas revenue was mainly generated from the sales business of APIs and intermediates.
Rundu Co., Ltd. (002923.SZ): Normethorphine hydrochloride injection is currently still in the registration and approval stage with the State Drug Administration
Gelonghui March 8, 丨 Rundu Co., Ltd. (002923.SZ) held an investor relationship on March 6, 2024 to discuss “Is this normethacidine hydrochloride injection product interested in expanding overseas markets?” The company replied that the normethorphine hydrochloride injection is currently still in the registration and approval stage with the State Drug Administration. In the future, based on domestic market development and sales, the possibility of expanding overseas markets is not ruled out.
Zhuhai Rundu Pharmaceutical Co., Ltd.'s (SZSE:002923) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Most readers would already be aware that Zhuhai Rundu Pharmaceutical's (SZSE:002923) stock increased significantly by 32% over the past month. We wonder if and what role the company's financials pla
Rundu Co., Ltd. (002923.SZ): Application for marketing license for normethacin hydrochloride injection was accepted
Gelonghui, March 4, 丨 Rundu Co., Ltd. (002923.SZ) announced that recently, Zhuhai Rundu Pharmaceutical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration, and the application submitted by the company for licensing the marketing of the drug normethorphine hydrochloride injection (“this product”) was accepted by the State Drug Administration. This product can be used as a cardiac stress test drug for nuclide myocardial perfusion imaging to assist in diagnosis and evaluation of myocardial ischemia.
Rundu Co., Ltd. (002923.SZ): Olmesartan hydrochlorothiazide tablets obtained a drug registration certificate
Gelonghui March 1 | Rundu Co., Ltd. (002923.SZ) announced that the company recently received the “Drug Registration Certificate” for olmesartan ester hydrochlorothiazide tablets issued by the State Drug Administration. This product is suitable for the treatment of high blood pressure. It is suitable for patients with inadequate control of blood pressure with olmesartan ester or hydrochlorothiazide alone. This product is a fixed dose compound preparation and is not suitable for initial treatment of high blood pressure. This product can be used alone or in combination with other antihypertensive drugs.
Rundu Co., Ltd. (002923.SZ): No studies have been conducted on the application of normethamine hydrochloride in the treatment and prevention of Alzheimer's disease
Gelonghui, Feb. 29丨Rundu Co., Ltd. (002923.SZ) said on an interactive platform that the company has not studied the application of normethacin hydrochloride in the treatment and prevention of Alzheimer's disease.
Rundu Co., Ltd. (002923.SZ): Levobupivacaine hydrochloride injection (5ml: 37.5mg) passed the generic drug consistency evaluation
Gelonghui, Feb. 28, 丨 Rundu Co., Ltd. (002923.SZ) announced that the company recently received the “Drug Supplement Application Approval Notice” for levobupivacaine hydrochloride injections issued by the State Drug Administration. After review, this product passed the consistent evaluation of generic drug quality and efficacy. At the same time, the following changes were agreed: 1. Change the drug production process; 2. Change packaging materials and containers directly in contact with drugs; 3. Change drug quality standards. Levobupivacaine is a long-acting amide local anesthetic and pain reliever. It is an isomer of the local anesthetic bupivacaine, mainly through voltage-sensitive sodium channels with the cell surface
Rundu Co., Ltd. (002923.SZ): Voriconazole dry suspension obtained drug registration certificate
Gelonghui, Feb. 5, 丨 Rundu Co., Ltd. (002923.SZ) announced that the company recently received a “Drug Registration Certificate” for voriconazole suspension issued by the State Drug Administration. Voriconazole dry suspension is a broad-spectrum triazole antifungal drug. It is suitable for treating the following fungal infections in adults and children aged 2 and over: 1. Invasive aspergillosis. 2. Candidiasis in non-neutropenic patients. 3. Serious invasive infections caused by fluconazole-resistant Candida (including Candida crudens). 4. Serious infections caused by Actinomycetes and Fusarium spp. This product is mainly used for progressive
Zhuhai Rundu Pharmaceutical Co., Ltd.'s (SZSE:002923) 25% Dip In Price Shows Sentiment Is Matching Earnings
To the annoyance of some shareholders, Zhuhai Rundu Pharmaceutical Co., Ltd. (SZSE:002923) shares are down a considerable 25% in the last month, which continues a horrid run for the company. The dr
Rundu Co., Ltd. (002923.SZ) issued a pre-reduction. Net profit for 2023 is expected to drop 49% to 56% year-on-year
Rundu Co., Ltd. (002923.SZ) announced its 2023 annual results forecast. It is expected to be owned by listed company shareholders for the whole year...
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Zhuhai Rundu Pharmaceutical Co., Ltd. (SZSE:002923) shareholders have seen the share price descend 20% over the month. While that's not great, the returns over five years have been decent. It's go
Rundu Co., Ltd. (002923.SZ): Esomeprazole magnesium obtained a notice of approval of the marketing application for chemical raw materials
Gelonghui November 24丨Rundu Co., Ltd. (002923.SZ) announced that the company recently received the “Notice of Approval of the Marketing Application for Chemical APIs” of esomeprazole magnesium approved and issued by the State Drug Administration. Esomeprazole magnesium is used to control gastroesophageal reflux disease and its symptoms, and is also used for erosive reflux esophagitis. Combined with appropriate antimicrobials, Helicobacter pylori can be eradicated, thereby healing peptic ulcers associated with its infection and preventing recurrence.
Analysis
Price Target
No Data
